About Intellia Therapeutics, Inc. - Common Stock (NTLA)
Intellia Therapeutics is a biotechnology company focused on developing innovative gene-editing therapies to treat serious genetic diseases. The company leverages its proprietary CRISPR/Cas9 technology platform to create precise and effective treatments that have the potential to address the root causes of diseases. By advancing its research and clinical programs, Intellia aims to pioneer new therapeutic approaches that could significantly improve patient outcomes and transform the landscape of genetic medicine. Read More
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs.
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.
